Ebronucimab vs Ongericimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Ebronucimab

Marketed by Hubei Jumpcan Pharmaceutical and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Partial signal

NCT05255094 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Reported efficacy

Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)

Result source: NCT05255094

Ongericimab · Junshida

Marketed by Shanghai Junshi Bioscience

Phase 3 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Reliable signal

NCT04781114 · Phase 3 · completed

This large, randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint was clearly met: both ongericimab dose regimens produced large, statistically significant reductions in LDL cholesterol versus placebo.

Reported efficacy

Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and week 24): Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001) (met)

Result source: NCT05325203

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEbronucimabOngericimab
LDL-C, % change—Not posted · NCT05260411—Not posted · NCT05532800
Non-HDL-C, % change—Not posted · NCT05260411—Not posted · NCT05532800
ApoB, % change—Not posted · NCT05260411—Not posted · NCT05532800
Lp(a), % change—Not posted · NCT05260411—Not posted · NCT05532800
3-point MACE (% with event)—Not posted · NCT05260411—Not posted · NCT05532800

LDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Ongericimab
—Not posted · NCT05532800

Non-HDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Ongericimab
—Not posted · NCT05532800

ApoB, % change

Ebronucimab
—Not posted · NCT05260411
Ongericimab
—Not posted · NCT05532800

Lp(a), % change

Ebronucimab
—Not posted · NCT05260411
Ongericimab
—Not posted · NCT05532800

3-point MACE (% with event)

Ebronucimab
—Not posted · NCT05260411
Ongericimab
—Not posted · NCT05532800
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint

Coverage. Ebronucimab: 1 of 1 rows · Ongericimab: 1 of 1 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEbronucimabOngericimab
LDL-C
percent change · % of baseline
No placebo or comparator arm
-59.13% @ 12wk450 mg Q4Wa,b,c
NCT05255094 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
-60.43% @ 12wk150 mg Q2W
NCT05255094 · Phase 3 · sponsor-reported, not registry data
-71.1% @ 12wka,b,c
NCT05532800 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
-72.7% @ 12wk
NCT05532800 · Phase 3 · sponsor-reported, not registry data

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Ongericimab's landscape